August 14, 2015
1 min read
Save
This article is more than 5 years old. Information may no longer be current.
Phase 3 study of EBI-005 for treatment of allergic conjunctivitis underway
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
The first patients in a phase 3 study have been dosed with EBI-005 for the treatment of moderate to severe allergic conjunctivitis, Eleven Biotherapeutics announced in a press release.
The pivotal trial is designed to evaluate the safety and efficacy of EBI-005 for up to 4 weeks. The multicenter, double-masked, randomized, vehicle-controlled study will include about 250 patients with moderate to severe allergic conjunctivitis who will be randomized to treatment with either EBI-005 or vehicle.
Top-line data are expected in the first quarter of 2016. The company expects to initiate a second phase 3 trial in the second half of 2016 if the results are favorable, the release said.